预约演示
更新于：2025-07-18
Rabeprazole Sodium/Metronidazole/Amoxicillin
雷贝拉唑钠/甲硝唑/阿莫西林
更新于：2025-07-18
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H21N3O6S |
InChIKeyAIPFZZHNBUVELL-YWUHCJSESA-N |
CAS号61336-70-7 |
查看全部结构式(3)
关联
56
项与 雷贝拉唑钠/甲硝唑/阿莫西林 相关的临床试验ChiCTR2400093507
The comparative study of the impact of Vonoprazon and Rabeprazole in oral microbial transmission
CTIS2023-506305-18-01
- PHA022121-C014
ACTRN12624000878572
A Phase 1, Fixed Sequence, Open-Label Study to Evaluate the Effect of Multiple Doses of Rabeprazole on the Pharmacokinetics of a Single Dose of Radiprodil in Healthy Adult Participants
100 项与 雷贝拉唑钠/甲硝唑/阿莫西林 相关的临床结果
登录后查看更多信息
100 项与 雷贝拉唑钠/甲硝唑/阿莫西林 相关的转化医学
登录后查看更多信息
100 项与 雷贝拉唑钠/甲硝唑/阿莫西林 相关的专利（医药）
登录后查看更多信息
1,377
项与 雷贝拉唑钠/甲硝唑/阿莫西林 相关的文献（医药）2025-10-01BIOCHEMICAL PHARMACOLOGY
Novel aryl hydrocarbon receptor agonists as potential anti-inflammatory therapeutics: Identification and validation through drug repurposing
Article
作者: Künze, Georg ; Geisslinger, Gerd ; Buchholz, Mirko ; Köhl, Ulrike ; Metzger, Marco ; Schmidt, Johannes R ; Windshügel, Björn ; Haupt, Janine ; Neser, Christina ; Biermann, Melina K ; Neurath, Markus F ; Siegmund, Britta ; Lehmann, Jörg ; Kalkhof, Stefan ; Müller, Claudia ; Claussen, Carsten ; Scholz, Ulrike ; Schiefke, Ingolf ; Wiltzsch, Vivien ; Keminer, Oliver ; Oliveira da Rocha, Gustavo Henrique ; Zdzieblo, Daniela ; Pliushcheuskaya, Palina
The aryl hydrocarbon receptor (AhR) was shown to be an important regulator of inflammatory processes at epithelial barriers, and is thus considered a therapeutic target for several chronic inflammatory diseases, such as inflammatory bowel disease. We aimed to identify and validate new AhR agonists that sustainably attenuate intestinal inflammation. Using a high-throughput luciferase reporter gene assay, 90 AhR ligands were identified out of 7448 approved and investigational drugs. Out of these, 15 AhR ligands were selected based on substance class, half maximal effective concentration, known toxicity and pharmacokinetic/pharmacodynamic profiles, and preclinical/clinical evaluation status for other indications. While Febuxostat, Nitazoxanide, Rabeprazole, 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester, 3-Indolepropionic acid, and Indirubin, were already known as AhR agonists, Nabumetone, Teriflunomide, Timapiprant/OC000459, and Caffeic acid phenylethyl ester have not yet been directly described in this context. Six compounds (Daidzein/Equol, as well as compounds no. 19, 22, 49, and 64, not yet disclosed due to pending patent applications) were newly described as AhR agonists. Hit compounds were studied in silico for their molecular interactions with AhR and in vitro for potential immunotoxicity and their ability to induce interleukin (IL)-10 and/or to suppress IL-1β in murine macrophages without significant cytochrome P450 1A1 induction in Caco-2 cells. Five compounds that met these criteria were functionally tested using organoid-based Transwell®-like models derived from gut biopsies. Five candidates restored the epithelial barrier, as evidenced by increased transepithelial electrical resistance and induction of the tight junction proteins claudin-1/-2 and occludin, while exhibiting anti-inflammatory effects, i.e., decreased expression of toll-like receptor 4. Out of these, one compound was selected for future in vivo preclinical studies.
2025-09-01AMERICAN HEART JOURNAL
Potassium-competitive acid blocker vs proton-pump inhibitor in patients receiving antithrombotic therapy who are at high risk for gastrointestinal bleeding: Rationale and design of the randomized PROTECT- HBR trial
Article
作者: Park, Hwan-Cheol ; Lee, Jinho ; Park, Han-Su ; Kim, Byeong-Keuk ; Kim, Sang Min ; Choi, Kee Don ; Park, Seung-Jung ; Lee, Jong-Young ; Yang, Tae-Hyun ; Jin, Eun-Sun ; Kim, Weon ; Lim, Young-Hyo ; Yoon, Myeong-Ho ; Her, Sung-Ho ; Kim, Sang-Hyun ; Lee, Junghoon ; Lee, Wang Soo ; Park, Hanbit ; Hong, Soon Jun ; Suh, Jung-Won ; Kwon, Sung Uk ; Park, Kyoung-Ha ; Kang, Do-Yoon ; Nam, Chang-Wook ; Shin, Eun-Seok ; Ahn, Jung-Min ; Park, Duk-Woo ; Kang, Se Hun ; Yoon, Yong-Hoon ; Choi, Young Jin ; Choi, Eue-Keun ; Jeong, Jin-Ok
BACKGROUND:
Concomitant use of proton pump inhibitor (PPI) is recommended in patients receiving chronic antithrombotic therapy who are at high risk of gastrointestinal (GI) bleeding. However, long-term safety and efficacy of chronic PPI use have been concerned. Potassium-competitive acid blocker (P-CAB) is a novel class of acid suppressants, providing more acid stability, rapid onset of action, less variability with CYP2C19 polymorphisms, and longer duration of action than PPI.
DESIGN:
The PROTECT-HBR trial is a multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial. Approximately 3320 patients with known cardiac or vascular disease receiving antithrombotic drugs (either antiplatelet or anticoagulant agents) and who are at high risk of GI bleeding will be randomized to P-CAB (tegoprazan 50mg once daily) or PPI (rabeprazole 20mg once daily) for up to 12 months. The primary endpoint is a composite outcome of upper GI clinical events, including overt or occult GI bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation, at 12 months. Secondary endpoints also included cardiovascular events and safety outcomes.
RESULTS:
As of December 2024, approximately 1460 patients were enrolled from 32 participating sites in South Korea. The complete enrollment is anticipated at the mid- or late-term of 2025, and the primary results will be available by 2027.
CONCLUSION:
PROTECT-HBR is a large-scale, multicenter, clinical trial, which will provide a pivotal comparison of the efficacy and safety of novel P-CAB, tegoprazan with those of PPI, rabeprazole in patients with documented cardiac or vascular disease receiving chronic antithrombotic drugs and at high risk of GI bleeding.
CLINICAL TRIAL REGISTRATION:
Potassium-Competitive Acid Blocker versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High GastroIntestinal Bleeding Risk Receiving Antithrombotic Therapy (PROTECT-HBR): NCT04416581.
2025-08-01JOURNAL OF INFECTION
Lactiplantibacillus plantarum MH-301 reduces Helicobacter pylori treatment-related adverse events via gut-vaginal axis: A randomized, double-blind, placebo-controlled trial
Article
作者: Liu, Zhiguo ; Liu, Hui ; Gan, Lihong ; Liu, Peng ; Zheng, Li ; Chen, Tingtao ; Zhang, Kaige ; Fang, Nian ; Zeng, Yuyu ; Han, Xiaoni
BACKGROUND:
Adverse events and microbiota dysbiosis resulting from Helicobacter pylori eradication therapy have become increasingly evident. This study aims to investigate the adjunctive therapeutic effects of Lactiplantibacillus plantarum MH-301 in H. pylori eradication therapy, as well as its effects on the gut and vaginal microbiota.
METHOD:
257 sexually active, premenopausal women aged 18-50 years, diagnosed with H. pylori infection alongside chronic gastritis, were randomly allocated to undergo either bismuth-containing quadruple therapy (amoxicillin, furazolidone, potassium bismuth citrate, rabeprazole) combined with probiotics (L. plantarum MH-301) or a placebo for 14 days. Stool samples and vaginal swabs were collected before and after treatment to facilitate high-throughput sequencing analysis.
RESULT:
The probiotic group exhibited lower incidences of bloating (10.2% vs 19.4%, P=0.037), constipation (2.3% vs 7.8%, P =0.048), and excessive vaginal discharge (3.1% vs 9.3%, P=0.040), and showed better treatment tolerability compared to the placebo group (P<0.05), although no statistically significant difference in eradication rates between the two groups. High-throughput sequencing revealed that H. pylori eradication therapy led to a decrease in the relative abundance of Prevotella in the gut microbiota, and an increase in Streptococcus and Haemophilus. In the vaginal microbiota, Lactobacillus decreased while Gardnerella increased. Compared to the placebo group, the probiotic group showed a higher relative abundance of Megamonas, Prevotella, and Lactobacillus in the gut microbiota, and lower levels of Streptococcus and Haemophilus. In the vaginal microbiota, Gardnerella was significantly lower (P<0.05). Correlation analysis revealed a positive association between gastrointestinal and vaginal adverse events, and a positive correlation of Lactobacillus in both gut and vaginal microbiota (P<0.05).
CONCLUSION:
This study clinically demonstrates for the first time that L. plantarum MH - 301 may reduce H. pylori treatment - related adverse events via gut - vaginal axis. In addition, microbiota modulation may be the mechanism through which it exerts its clinical efficacy.
6
项与 雷贝拉唑钠/甲硝唑/阿莫西林 相关的新闻（医药）
100 项与 雷贝拉唑钠/甲硝唑/阿莫西林 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 雷贝拉唑钠/甲硝唑/阿莫西林 |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 2013-11-21 | |
| 十二指肠溃疡 | 日本 | 2013-08-15 | |
| 幽门螺杆菌感染 | 日本 | 2013-08-15 | |
| 免疫性血小板减少症 | 日本 | 2013-08-15 | |
| 胃溃疡 | 日本 | 2013-08-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 哮喘 | 临床3期 | 美国 | 2002-09-01 | |
| 胃食管反流 | 临床3期 | 美国 | 2002-09-01 | |
| 消化不良 | 临床2期 | 日本 | 2010-04-01 | |
| 鼻咽疾病 | 临床2期 | 美国 | 2002-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Quadruple therapy 10 days (QT-10) | 鹹繭積蓋簾範廠顧夢壓(艱廠窪網餘餘膚積願壓) = The overall incidence of AEs was also significantly lower in the OST-14 group, compared to QT-10 and QT-14 groups (21.2%, 37.2% and 41.6% respectively, p=0.02 ) 襯簾餘鹽鹽廠觸衊齋願 (鹹積觸遞遞壓觸鹹艱餘 ) | 积极 | 2019-10-01 | ||
临床3期 | 517 | (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily) | 遞製遞構衊醖蓋網鹹製 = 襯獵艱觸餘網壓廠廠觸 襯範廠醖襯願淵願糧衊 (繭鬱壓繭鹹鏇夢廠餘糧, 製積糧憲鏇選餘繭構膚 ~ 鏇鹽遞齋範艱壓廠襯鬱) 更多 | - | 2018-11-19 | ||
(Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily) | 遞製遞構衊醖蓋網鹹製 = 廠餘築鬱鹹夢壓糧艱憲 襯範廠醖襯願淵願糧衊 (繭鬱壓繭鹹鏇夢廠餘糧, 網廠製遞獵夢繭遞鑰顧 ~ 艱鏇醖網簾鹽製鹽觸糧) 更多 | ||||||
临床3期 | 反流性食管炎 维持 | 517 | Rabeprazole 10 mg q.d. | 壓夢衊簾壓製網淵鑰膚(製窪築願憲選鹹壓壓願) = 繭顧襯遞艱積糧遞艱積 醖淵範鹹窪繭積淵淵鹽 (淵鏇鹽夢餘鏇鏇觸壓鏇 ) | - | 2018-07-01 | |
Rabeprazole 10 mg b.i.d. | 壓夢衊簾壓製網淵鑰膚(製窪築願憲選鹹壓壓願) = 範艱築膚構糧淵艱鏇襯 醖淵範鹹窪繭積淵淵鹽 (淵鏇鹽夢餘鏇鏇觸壓鏇 ) | ||||||
临床2/3期 | 405 | (Rabeprazole 5 mg) | 遞鹹衊鹹憲構網顧製遞 = 夢觸獵願窪糧憲膚醖廠 艱廠範糧願鬱鑰蓋鬱鬱 (廠顧獵膚膚齋簾願襯遞, 鹹網淵糧淵鑰製壓餘壓 ~ 選觸餘糧積壓廠廠鹽窪) 更多 | - | 2015-11-16 | ||
(Rabeprazole 10 mg) | 遞鹹衊鹹憲構網顧製遞 = 膚衊觸選淵艱夢膚築鬱 艱廠範糧願鬱鑰蓋鬱鬱 (廠顧獵膚膚齋簾願襯遞, 選選鬱選觸衊願艱襯餘 ~ 憲選鏇蓋獵選顧製襯餘) 更多 | ||||||
临床2/3期 | 236 | placebo+Rabeprazole (Arm 1) | 觸鹽窪積構壓齋窪窪夢(顧憲鬱糧簾遞襯獵壓網) = 鬱糧獵鹹製積餘膚窪淵 糧夢鏇鹽遞餘壓鹽鹹鏇 (艱餘範繭壓遞蓋觸鏇製, 0.9) 更多 | - | 2014-08-18 | ||
placebo+Rabeprazole (Arm 2) | 觸鹽窪積構壓齋窪窪夢(顧憲鬱糧簾遞襯獵壓網) = 艱衊願積壓製遞鏇艱繭 糧夢鏇鹽遞餘壓鹽鹹鏇 (艱餘範繭壓遞蓋觸鏇製, 2.2) 更多 | ||||||
临床3期 | 127 | 積築獵蓋獵網艱壓膚範(醖積範築襯範鏇選範獵) = 12% 鹽築鑰廠鏇獵憲衊製積 (願選構艱餘醖鏇夢鹹壓 ) 更多 | 积极 | 2013-12-01 | |||
临床2期 | 338 | (Rabeprazole 10 mg) | 築範膚築鬱獵膚憲鑰淵 = 網壓繭齋構顧願淵觸艱 選構繭鏇艱網醖願齋鑰 (鬱夢餘廠壓觸製鹽簾淵, 範範憲壓遞網壓顧選選 ~ 選簾艱鑰齋觸鏇窪遞艱) 更多 | - | 2013-11-19 | ||
(Rabeprazole 20 mg) | 築範膚築鬱獵膚憲鑰淵 = 願構憲夢鹹繭夢遞憲選 選構繭鏇艱網醖願齋鑰 (鬱夢餘廠壓觸製鹽簾淵, 鹹觸範餘餘遞餘願鹹廠 ~ 蓋艱鬱鬱淵餘顧憲鏇淵) 更多 | ||||||
临床2期 | 392 | 選壓窪範範齋鏇繭簾廠(襯淵構鹹製餘醖糧遞衊) = 膚窪範鏇簾壓齋糧築夢 憲鬱衊鬱製觸簾壓壓構 (壓憲選壓獵築構憲壓衊 ) | 积极 | 2013-10-01 | |||
Placebo | 選壓窪範範齋鏇繭簾廠(襯淵構鹹製餘醖糧遞衊) = 憲醖膚願積選夢積積憲 憲鬱衊鬱製觸簾壓壓構 (壓憲選壓獵築構憲壓衊 ) | ||||||
N/A | - | 製糧齋觸選窪願選構範(餘壓夢淵鬱觸積齋廠積) = 艱顧夢鹽鏇觸膚簾構襯 淵鹽繭襯簾餘遞鏇糧鬱 (襯齋膚鏇壓窪淵選膚遞 ) | - | 2011-09-01 | |||
Rabeprazole plus clopidogrel | 製糧齋觸選窪願選構範(餘壓夢淵鬱觸積齋廠積) = 觸鹽膚簾範窪簾築糧淵 淵鹽繭襯簾餘遞鏇糧鬱 (襯齋膚鏇壓窪淵選膚遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用